![The breaking news round-up: Decagear launches today, Pimax announces new headsets, and more! [APRIL FOOL’S]](https://i0.wp.com/skarredghost.com/wp-content/uploads/2025/03/lawk_glasses_handson.jpg?fit=1366%2C1025&ssl=1)
Pfizer Stops Work on Oral GLP-1 Obesity Drug After Safety Signal Surfaces in Clinical Trial
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial. The post Pfizer Stops Work on Oral GLP-1 Obesity Drug After Safety Signal Surfaces in Clinical Trial appeared first on MedCity News.
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.
The post Pfizer Stops Work on Oral GLP-1 Obesity Drug After Safety Signal Surfaces in Clinical Trial appeared first on MedCity News.
